NCT05047146

Brief Summary

This study aimed at study the clinical and pathological criteria of Hepatocellular carcinoma to keep with new challenging in diagnosis and morpho-molecular classifications

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
530

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

September 2, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

September 16, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2021

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2022

Completed
Last Updated

October 25, 2022

Status Verified

October 1, 2022

Enrollment Period

10 months

First QC Date

September 2, 2021

Last Update Submit

October 23, 2022

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (5)

  • Clinicopathological factors of Hepatocellular Carcinoma

    Serum alpha-fetoprotein (AFP) level

    10 years

  • Clinicopathological factors of Hepatocellular Carcinoma

    Tumor size and focality

    10 years

  • Clinicopathological factors of Hepatocellular Carcinoma

    Vascular invasion

    10 years

  • Clinicopathological factors of Hepatocellular Carcinoma

    Pathologic stage and grade

    10 years

  • Clinicopathological factors of Hepatocellular Carcinoma

    The reserve of background liver

    10 years

Interventions

Morphological classifications of HCCOTHER

Morphological classifications of Hepatocellular carcinoma

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

HCC cases from a single tertiary center eligible for pathological analysis as a primary tool

You may qualify if:

  • All pathologically proven Hepatocellular Carcinoma

You may not qualify if:

  • Other malignant tumors than Hepatocellular Carcinoma
  • Benign tumor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Liver Intitute

Shibīn al Kawm, Menoufia, 32511, Egypt

Location

Related Publications (1)

  • Sweed D, Sweed E, Moaz I, Mosbeh A, Fayed Y, Elhamed SMA, Sweed E, Macshut M, Abdelsattar S, Kilany S, Saied SA, Badr R, Abdallah MS, Ehsan N. The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt. World J Surg Oncol. 2022 Sep 19;20(1):298. doi: 10.1186/s12957-022-02764-2.

    PMID: 36117166DERIVED

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Clinical Pharmacy

Study Record Dates

First Submitted

September 2, 2021

First Posted

September 16, 2021

Study Start

January 1, 2021

Primary Completion

October 31, 2021

Study Completion

July 31, 2022

Last Updated

October 25, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will share

sharing will be by website or google after paper publication

Shared Documents
STUDY PROTOCOL, SAP

Locations

EG(1)